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Astrogliosis (i.e. glial scar), which is comprised primarily of
proliferated astrocytes at the lesion site andmigrated astrocytes
from neighboring regions, is one of the key reactions in deter-
mining outcomes after CNS injury. In an effort to identify
potential molecules/pathways that regulate astrogliosis, we
sought to determine whether Rac/Rac-mediated signaling in
astrocytes represents a novel candidate for therapeutic inter-
vention following CNS injury. For these studies, we generated
mice with Rac1 deletion under the control of the GFAP (glial
fibrillary acidic protein) promoter (GFAP-Cre;Rac1flox/flox).
GFAP-Cre;Rac1flox/flox (Rac1-KO) mice exhibited better recov-
ery after spinal cord injury and exhibited reduced astrogliosis at
the lesion site relative to control. Reduced astrogliosis was also
observed in Rac1-KO mice following microbeam irradiation-
induced injury. Moreover, knockdown (KD) or KO of Rac1 in
astrocytes (LN229 cells, primary astrocytes, or primary astro-
cytes fromRac1-KOmice) led to delayed cell cycle progression
and reduced cell migration. Rac1-KD or Rac1-KO astrocytes
additionally had decreased levels of GSPT1 (G1 to S phase tran-
sition 1) expression and reduced responses of IL-1 andGSPT1 to
LPS treatment, indicating that IL-1 and GSPT1 are down-
stream molecules of Rac1 associated with inflammatory con-
dition. Furthermore, GSPT1-KD astrocytes had cell cycle delay,
with no effect on cell migration. The cell cycle delay induced by
Rac1-KD was rescued by overexpression of GSPT1. Based on
these results, we propose that Rac1-GSPT1 represents a novel
signaling axis in astrocytes that accelerates proliferation in
response to inflammation, which is one important factor in the
development of astrogliosis/glial scar following CNS injury.
Astrocytes play important roles in the establishment and
maintenance of numerous brain functions, including control of
the blood-brain barrier; regulation of blood flow; supply of
energymetabolites to neurons; synaptic function; and extracel-
lular balance of ions, fluid, and transmitters (1). Astrocytes also
respond to numerous types of CNS injury, including trauma,
ischemia, infection, and neurodegenerative disease, through a
process commonly referred to as astrogliosis. Astrogliosis is
characterized by hypertrophic morphologic changes, acceler-
ated proliferation, and changes in gene expression (2, 3). The
degree of astrogliosis extends from reactive (transient) astro-
gliosis in mild cases to glial scar in severe cases (also involving
microglia, fibromeningeal cells, and inflammatory cells) (2).
Rac (Rac1–3) is a member of the Rho family of small
GTPases, which play fundamental roles in a wide variety of
cellular processes, including transcriptional regulation, cell
cycle progression, and cellmigration based on actin remodeling
(4, 5). In addition, Rac is an activator of three of the seven super-
oxide-generating NADPH oxidases (Nox; Nox1, Nox2, and
Nox3)4 (6, 7), and reactive oxygen species (ROS) generating
from superoxide are detrimental factors following CNS injury
(8–11). Nox2-KO mice exhibited reduced brain infarction fol-
lowing ischemia-reperfusion (12). Moreover, suppression of
renal infarction by a dominant negative Rac1 mutant (13) and
worsening of ischemia-reperfusion injury by cardiomyocyte-
specific overexpression of active Rac1 have been reported (14).
In astrocytes, expression of Nox2 and Nox4 has been described
(15). Collectively, Rac1 is a likely candidate to mediate the cel-
lular response to CNS injury through various cell types (includ-
ing neurons and glial cells) and pathways (including actin
remodeling, cell cycle progression, andNox-derived ROS) (16).
However, the effects and functions of Rac1 following CNS
injury, especially in astrocytes, remain unclear.
Spinal cord injury (SCI) is a traumatic CNS injury that causes
severe and persistent locomotor and sensory dysfunction (17).
SCI triggers a cascade of events, including infiltration ofmacro-
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phages, leukocytes, and lymphocytes into the lesion and prolif-
eration and migration of resident glial cells, astrocytes and
microglia, around the lesion site (18, 19). During the acute
phase of the injury, astrocytes increase in number and migrate
to the site of the injury to isolate the inflammatory region from
neighboring tissue. During the subacute and chronic phases,
astrocytes form a physical barrier that is referred to as a glial
scar particularly in severe SCI. The glial scar surrounding the
lesion has dual effects: a beneficial effect that minimizes the
inflammatory region during the acute phase of injury and a
detrimental effect that restricts neuronal regeneration during
the subacute and chronic phases of injury (18, 19). Thus, effi-
cient control of the degree of astrogliosis/glial scar and appro-
priate timing of therapeutic intervention to astrogliosis/glial
scar may be important for achieving better recovery from SCI.
To investigate whether the Rac/Rac-mediated signaling
pathway in astrocytes is a novel candidate for therapeutic
modalities following CNS injury, we generated astrocyte-spe-
cific Rac1-KO (GFAP-Cre;Rac1flox/flox) mice. Rac1-KO mice
exhibited better recovery from SCI and reduced astrogliosis
following CNS injury relative to control mice. Depletion or
deletion of Rac1 in astrocytes delayed cell cycle progression and
reduced cell migration. We also found that the GSPT1 (G1 to S
phase transition 1) protein is a downstream molecule of Rac1
signaling in astrocytes. GSPT1/eRF3 was first identified as a
molecule involved in the G1 to S phase transition in Saccharo-
myces cerevisiae (20). Subsequently, GSPT1 was reported to
mediate translation termination via the eRF1-eRF3 complex in
eukaryotes (21, 22). Expression levels and responses of IL-1
and GSPT1 to LPS treatment were reduced in astrocytes with
Rac1 depletion or deletion. GSPT1 depletion induced cell cycle
delay, and cell cycle delay induced by Rac1 depletion was res-
cued by overexpression of GSPT1. Thus, we propose that Rac1-
GSPT1 is a novel signaling axis that accelerates the prolifera-
tion of astrocytes during inflammation, which is one important
factor in the development of astrogliosis/glial scar after CNS
injury.
Results
Generation of Rac-KO Mice in Astrocytes—Among the three
members of Rac, only Rac1 mRNA was detected in astrocytes
by RT-PCR (Fig. 1A). Based on this result, we generated Rac1-
KO mice in astrocytes using GFAP-Cre transgenic mice (23)
and Rac1flox/flox mice (24), hereafter referred to as GFAP-
Cre;Rac1flox/flox (Rac1-KO) mice. KO of Rac1 in astrocytes was
confirmed by immunoblotting using primary astrocytes
obtained from Rac1-KO mice (Fig. 1B). Moreover, the pattern
of GFAP-Cre-driven recombination was assessed using
GFAP-Cre;Rac1flox/;tdTomato mice generated by the inter-
crossing of GFAP-Cre;Rac1flox/flox and CAG-STOPflox;tdTo-
matomice (Fig. 1,C andD). Fluorescence for tdTomato expres-
sion was positive in GFAP-positive astrocytes within the spinal
cords of GFAP-Cre;Rac1flox/;tdTomato mice but not control
(Rac1flox/;tdTomato) mice (Fig. 1E).
Better Recovery of Rac1-KO Mice after SCI—We developed
SCI in Rac1-KO mice via a contusion injury and evaluated the
locomotor capabilities of their hind limbs at 18 timepoints (1, 3,
5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 days
post-injury) over 35 days using 2 scoring systems: the 0–8-
point Basso Mouse Scale (BMS) score (25) and the 0–4-point
Body Support Scale (BSS) score (26). The BMS and BSS evalu-
ate hind limbmovement andbody support, respectively. Recov-
ery of locomotor capability after SCI was significantly better in
Rac1-KO mice compared with control mice for both scoring
systems. Better recovery in Rac1-KOmice was observed from 7
days after SCI (but not significant for BMS, p 0.124). Recov-
ery was statistically improved for both scores from 9 days after
SCI until 35 days after SCI (Fig. 2A).
To examine histological differences between Rac1-KO mice
and control mice, the spinal cord was fixed at 35 days after SCI.
GFAP immunoreactivity around the injury sites (100 m from
the lesion)was significantlyweaker in Rac1-KOmice compared
with control mice (Fig. 2B). As an alternative approach to dem-
onstrate GFAP immunoreactivity in Rac1-KO mice after CNS
injury, we applied microplanar beam irradiation (100-m
width at 550 Gy with 400-m gaps (center to center distance))
supplied from a Spring-8 synchrotron radiation facility (27) to
the cerebellar cortex and brainstem. The injury caused by high
energy X-rays is limited to a narrow region (27, 28). GFAP-
positive immunoreactivity in a linear band surrounding the
irradiated lesions was weaker in the brainstem of Rac1-KO
mice compared with control mice (Fig. 2C). Together these
FIGURE 1. Rac1-KO in astrocytes. A, RT-PCR was performed using cDNA
obtained fromWT primary astrocytes and specific primer-pairs of Rac1, Rac2,
and Rac3. The predicted sizes of the amplified Rac1, Rac2, and Rac3 bands are
454, 581, and 440 bp. NC, negative control (without cDNA). B, primary astro-
cytes obtained from control and GFAP-Cre;Rac1flox/flox (Rac1-KO) mice were
subjected to immunoblotting using a Rac1 antibody. Comparable loading of
proteins was confirmed using tubulin- antibody. C, spinal cords obtained
from GFAP-Cre;Rac1flox/;tdTomato mice were subjected to immunostaining
using a GFAP antibody followed by Alexa 488 secondary antibody and then
observed under a confocal laser microscope. Scale bar, 200m.D, magnified
images of the area indicated by the rectangles in C are shown. Scale bar, 100
m. E, spinal cords obtained from control (Rac1flox/;tdTomato) mice were
observed under a confocal laser microscope. DIC, differential interference
image. Scale bar, 200 m.
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results strongly suggest that immunoreactivity to GFAP,
namely astrogliosis, after CNS injury was reduced by Rac1-KO
in astrocytes.
Reduced Proliferation and Migration in Rac1-KD and
Rac1-KO Astrocytes—We hypothesized that reduced GFAP
immunoreactivity in two different CNS-injury models is due to
the reduced proliferation and/or migration following Rac1-KO
in astrocytes, thereby leading to reduced astrogliosis. To exam-
ine the contribution of Rac1 to cell cycle progression and cell
migration, we used the Fucci system (29) and scratch wound
assay, respectively, under a long term, time lapse live-imaging
system.
Rac1-KD in LN229 cells, a cell line derived from a human
glioblastoma, was achieved using a verified plasmid expressing
shRNA for Rac1 (6) (Fig. 3A). Cell cycle progression, defined as
the time from one cytokinesis to another cytokinesis, was sig-
nificantly longer in Rac1-KD LN229 cells than in control cells
(29.95 0.66 h versus 36.58 1.56 h; Fig. 3B). the G1 phase was
significantly extended by Rac1-KD (14.60  1.09 h versus
19.64 1.87 h); however, the S-M phase, defined by the green
fluorescence of Venus-tagged hGeminin, was not changed by
Rac1-KD (Fig. 3B).
Cell migration, evaluated using the scratch wound assay, was
also significantly reduced in Rac1-KD LN229 cells compared
with control cells (168.7 21.8 m versus 40.6 7.3 m) (Fig.
3C). Both delayed cell cycle progression and reduced cellmigra-
tion were also observed in Rac1-KD primary astrocytes (cell
cycle: 24.00  1.04 h versus 31.03  1.72 h, cell migration:
187.8 14.7 m versus 102.9 7.4 m) and in primary astro-
cytes obtained from Rac1-KO mice (cell cycle: 20.11  0.77 h
versus 27.59  1.12 h, cell migration: 349.1  12.9 m versus
172.3  11.4 m) (Fig. 4, A–C). The reduced cell migration in
Rac1-KO primary astrocytes was confirmed using a CytoSelect
cell migration assay kit (Fig. 4D).
GSPT1 Is a Downstream Effector of Rac1 Signaling—LPS has
been reported to induce Rac1-mediated up-regulation of vari-
ous proteins, including the pro-inflammatory cytokine IL-1
(30). IL-1 is a key driver of inflammatory response and astro-
gliosis induced by brain damage, including SCI (31) and ische-
mic brain injury (32). First, we confirmed increased protein
levels of IL-1 following LPS treatment in primary astrocytes
from WT mice, as well as reduced IL-1 expression following
LPS treatment in primary astrocytes from Rac1-KO mice.
These findings indicate the existence of a Rac1-dependent tran-
scriptional pathway enhanced by LPS treatment (Fig. 5A). Sec-
ond, to identify novel downstream molecules in Rac1 signaling
associated with the cell cycle and cell migration, we performed
a DNA microarray using control and Rac1-KD LN229 cells
treated with LPS (Fig. 5B), fromwhich reduced levels of GSPT1
in Rac1-KD cells were detected compared with control cells.
Decreased protein levels of GSPT1 were confirmed in LN229
cells using two different siRNAs for Rac1, as well as from pri-
mary astrocytes from Rac1-KO mice (Fig. 5C). In addition,
GSPT1 was increased after treatment with LPS, and the
decreased expression of GSPT1 following LPS treatment was
observed in Rac1-KD LN229 cells (Fig. 5C). Furthermore, the
increase in GSPT1 levels following LPS treatment was inhib-
ited by a JNK inhibitor (JNK-IN-8), an ERK inhibitor (U0126),
and an NF-B inhibitor (BAY 11-7085), but not by a p38 MAP
kinase inhibitor (SB203580) (Fig. 5E). These results suggest that
GSPT1 is transcriptionally regulated by Rac1 through the acti-
vation of at least JNK, ERK, and NF-B and that GSPT1 is up-
regulated and continues to function after CNS injury, which
induces inflammation.
The Rac1-GSPT1 Signaling Axis Is Involved in the Cell Cycle
but Not Cell Migration—To examine the role of Rac1 and
GSPT1 in cell cycle progression, we analyzed the cell cycle
under long term, time lapse live-imaging in HeLa cells (another
cell line rather than LN229). The cell cycle of HeLa cells was
significantly prolonged following KD using two different
siRNAs for GSPT1 (control: 18.47  0.36 h, si620: 22.93 
0.40 h, and si1374: 23.25  0.61 h) (Fig. 6, A and B). Further-
FIGURE 2. Better recovery of locomotor function after SCI and reduced
astrogliosisafterCNS injuries inRac1-KOmice.A, BMSandBSS scoreswere
recorded from days 1 to 35 after SCI. From day 9 after SCI, both hind limb
movement and body support capability in Rac1-KO mice were significantly
better than in control (cont) mice. This significant difference was sustained
until day 35 (control; n  14 hind limbs, Rac1-KO; n  10 hind limbs; *, p 
0.05; **, p 0.01; ***, p 0.001 by Bonferroni’s post hoc test following two-
way ANOVA). B, sagittal sections of spinal cords from control and Rac1-KO
mice 35 days after SCIwere immunostained using aGFAP antibody andAlexa
488 secondary antibody. Immunoreactivity to GFAP in the area 100-m ros-
tral and caudal from the edge of the lesion (indicated by red lines) is shown
(control; n 12 sections from3mice, Rac1-KO; n 12 sections from4mice; *,
p  0.0420). Scale bars, 100 m. C, coronal sections of the right cerebellum
and brainstem from control and Rac1-KOmice 21 days after microbeam irra-
diation injury (horizontally propagating multibeams, 100-m width with
400-m gaps between them) were immunostained using a GFAP antibody.
GFAP-positive immunoreactivity in a linear band surrounding the irradiated
lesions of the brainstem is shown (control; n 9 ROIs from 3 mice, Rac1-KO;
n 9 ROIs from3mice; **, p 0.0046). The right panels aremagnified images
of the regions indicatedby the rectangles in the left panels. Scale bars, 500m.
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more, the prolonged cell cycle induced by Rac1-KD (2.5 nM:
22.05 0.38 h, 5 nM: 22.38 0.44 h) in HeLa cells was amelio-
rated by overexpression of GFP-tagged GSPT1 (GFP-GSPT1)
(2.5 nM: 19.73 0.48 h, 5 nM: 19.76 0.41 h) (Fig. 6, C and D).
The delayed cell cycle progression was also observed in
GSPT1-KD primary astrocytes (20 nM; control: 24.02 0.82h,
si620m: 28.74 0.86 h; Fig. 6, E and F).
To determine whether GSPT1 controls cell migration, we
employed a scratch wound assay. Cell migration was not
affected by two siRNAs for GSPT1 in LN229 cells (Fig. 7, A
and B). The absence of an effect of GSPT1-KD on cell migra-
tion in primary astrocytes was also confirmed using a
CytoSelect cell migration assay kit (20 nM of si-cont and
siGSTP1–620m; Figs. 7, C and D). These results suggest that
GSPT1 is a downstream effector in Rac1 signaling and that
the Rac1-GSPT1 signaling axis is involved in cell cycle regu-
lation but not cell migration.
Discussion
Although current evidence suggests that astrogliosis is ben-
eficial during the initial/early/acute stages of CNS injury by
isolating the lesion from inflammation, astrogliosis is detrimen-
tal at later/chronic stages of injury because of inhibition of neu-
ral regeneration (18). Activation of astrocytes, which results in
glial scar after severe CNS injury, starts with immediate infil-
tration of macrophages/leukocytes/lymphocytes to the lesion
and activation of microglia. However, this activation persists
longer than those reactions to isolate and sequester the inflam-
mation (18).
In the present study, Rac1-KO mice exhibited better func-
tional recovery than controlmice, starting from7days after SCI
(statistically significant from9days after SCI) until 35 days after
SCI (Fig. 2A). Rac1-KOmice also exhibitedmild suppression of
astrogliosis at 35 days following SCI compared with control
mice. In contrast, severely reduced astrogliosis after SCI was
reported in conditional STAT3-KO mice, resulting in remark-
ably worse motor deficits than control mice (33, 34). Thus,
mildly suppressed astrogliosis may lead to reduced detrimental
effects of astrogliosis during the chronic stages of SCI. In addi-
tion to mildly suppressed astrogliosis at 35 days after SCI in
Rac1-KO mice, Rac1-KO astrocytes also exhibited reduced
production of IL-1 following LPS treatment. Inhibition of
C5aR, a G-protein-coupled receptor for complement protein
C5a, was reported to have dual effects on locomotor recovery
after SCI: a beneficial effect in the first 7 days after SCI by inhib-
iting production of various pro-inflammatory cytokines,
including IL-1, and a detrimental effect after the first 7 days by
inhibiting astrogliosis (35). Thus, better functional recovery
after SCI in Rac1-KO mice may be due to the dual beneficial
effects of Rac1 against inflammation in the acute/subacute
phase and astrogliosis in the subacute/chronic phase.
FIGURE 3. Delayed cell cycle and impaired migration in Rac1-KD LN229 astrocytic cells. A, 48 h after transfection of LN229 cells (pSUPER (sh-cont) or
shRac1(618)), efficacy of shRac1(618) on Rac1 expression levels was evaluated using a Rac1 antibody. Comparable loading of proteins was confirmed using a
tubulin- antibody. B, from 24 to 96 h after transfection (pSUPER(rfp) (sh-cont) or shRac1(618rfp)), the cell cycle of the RFP-expressing cells was evaluated using
a Fucci system (upper left panel) and an LCV110microscope. The cell cycle time (i.e. doubling time) is shown in the upper right panel (control: n 57, Rac1-KD:
n 39; **, p 0.0003). The lower left panel shows the cell cycle timeof theG1 phase (control: n 15, Rac1-KD: n 16). The lower right panel shows the cell cycle
time from the S to M phase (control: n 15, Rac1-KD: n 16; *, p 0.0292). C, from 48 to 96 h after transfection (pSUPER(gfp) (sh-cont) or shRac1(618gfp)),
migration capabilities of the GFP-expressing cells weremonitored using an LCV110microscope (0 h: starting time point, 48 h: ending time point, control: n
17, Rac1-KD: n 31; **, p 0.0001). Thewhite lines are located at the same position at time 0 and 48 h to show the movement (indicated by purple arrows at
48 h) of the cells marked by filled purple circles at 0 h. Scale bar, 200 m.
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The main compartment of the glial scar is believed to be
formed by proliferated astrocytes around the lesion, as well as
infiltrating astrocytes from neighboring regions (18, 33). In
contrast, using a stab wound cortical injury model, which is
probably a weaker injury than SCI or brain infarction, Bardehle
et al. (36) have shown that astrogliosis is not associated with
astrocyte migration from neighboring regions. In addition, the
authors report that astrocyte proliferation in the specific jux-
tavascular niche in the brain parenchyma may play important
roles in astrogliosis. Although further study is required for con-
clusions regarding the contribution of astrocytemigration from
neighboring regions in astrogliosis after SCI or brain infarction,
in the present study, we found that Rac1 regulates both the
proliferation and migration of astrocytic cells. Involvement of
Rac1 in cell migration is well studied (37, 38); however, the
precise mechanism regulating cell proliferation by Rac1
remains unclear. Although Rac1 was reported to be a negative
regulator in cytokinesis (39, 40), we found delayed cell cycle
progression, in particular an elongated G1 phase, induced by
Rac1-KD. Promotion of G1 to S phase transition by Rac1 was
reported to be regulated via increased levels of cyclin D1 (41,
42) through either NF-B-dependent (5, 43) or independent
(44) mechanisms. Chauvin et al. (45) reported that GSPT1
depletion induced decreased levels of cyclin D1 by inhibition of
translation initiation via the mTORC1 pathway, which pro-
motes translation initiation rather than inhibition of transla-
tion termination. Although the precise mechanism responsible
for the Rac1 control of GSPT1 levels is still unknown, GSPT1
may be transcriptionally regulated by Rac1 through the activa-
tion of JNK, ERK, and NF-B, but not p38 MAP kinase. Thus,
the Rac1-GSPT1 signaling axis plays a critical role for astroglial
growth.
In addition to the involvement of GSPT1 in the cell cycle,
GSPT1 has been reported to be involved in cell migration (46,
47). However, no effect of GSPT1 KD on cell migration was
observed in the present study. The reason for the discrepancy
between the present study and previous reports is unknown but
may be due to the specific cell lines used. Xiao et al. (47)
reported that HCT116 colorectal cancer cells exhibited high
level expression of GSPT1. Given the significant reduction of
migration in Rac1-KD/KO, but not GSPT1-KD, astrocytes,
GSPT1 is unlikely to be involved in cell migration in this
context.
Rac1 is a known tumor progression factor because of its roles
in cell migration/invasion and cell proliferation (48, 49).
Recently, several activating mutations of RACs, including
RAC1 and RAC2, have been reported as oncogenic driver genes
in human melanoma and cancer cell lines (50–52). More
recently, genome-wide association studies have shown that tes-
ticular germ cell tumors are susceptible to increased GSPT1
FIGURE 4. Delayed cell cycle and impaired migration in both Rac1-KD and Rac1-KO primary astrocytes. A, left panel, 60 h after electroporation of 20 nM
siRNA (si-cont or siRac1(618)GFP plasmid) intoWTprimary astrocytes, Rac1 expression levels were evaluated using a Rac1 antibody. Comparable loading of
proteins was confirmed using a GAPDH antibody. Right panel, primary astrocytes obtained from Rac1flox/flox;tdTomato (control, cont) andGFAP-Cre;Rac1flox/flox;
tdTomato (Rac1-KO)micewere subjected to immunoblotting using a Rac1 antibody. Comparable loading of proteinswas confirmed using aGAPDH antibody.
B, the cell cyclewas evaluatedusing an LCV110microscope from48 to 120h after electroporation in the experiment usingWTprimary astrocytes (siRNAGFP
plasmid) or after thepreparationonaglass-bottomeddish in the experimentusingprimary astrocytes fromRac1-KO (with tdTomato) and controlmice. The left
pair and the right pair in thegraph showdata obtainedusingRac1-KDastrocytes (control:n79, Rac1-KD:n40; **,p0.0003) andusingRac1-KOastrocytes
(control: n 80, Rac1-KO: n 82; **, p 0.0001), respectively. C, 48–120 h after electroporation in the experiment usingWT primary astrocytes (siRNAGFP
plasmid) or in the preparation on the glass-bottomed dish in the experiment using primary astrocytes from Rac1-KO (with tdTomato) and control mice, cell
migration capabilities were evaluated using an LCV110microscope. The left pair and the right pair in the graph show data obtained using Rac1-KD astrocytes
(control: n 31, Rac1-KD: n 65; **, p 0.0001) and using Rac1-KO astrocytes (control: n 47, Rac1-KO: n 39; **, p 0.0001), respectively. D, 24 h after
preparing the primary astrocytes from control and Rac1-KOmice in 24-well insets, cell migration capabilities were assayed using a CytoSelect migration assay
kit (control: n 10, Rac1-KO: n 6; **, p 0.0001).
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expression (53). Given the novel Rac1-GSPT1 signaling axis
found in the present study, GSPT1 may participate in an onco-
genic mechanism as a downstream target of active RAC1.
Although Rac1-GSPT1 signaling is involved in cell cycle pro-
gression from G1 to S phase, namely cell proliferation, this
involvement does not seem to explain the entirety of the effects
of Rac1 on better recovery of Rac1-KO mice after SCI. Cooney
et al. (54) reported that the Nox that is most responsive in
astrocytes and microglia after SCI is Nox2, a Rac1-activated
Nox; in contrast, the expression of Nox4, a Rac-independent
Nox, was constant over time in astrocytes. The group reported
an increase inNox2 in astrocytes at 24 h and 7 days after SCI, as
well as reduced expression of pro-inflammatory cytokines via
the systemic administration of a Nox2 inhibitor (54). Thus,
Rac-activated Nox2 in astrocytes may be one factor that
induces better recovery of Rac1-KO mice after SCI.
In summary, we found that amild suppression of astrogliosis
promotes better functional recovery after SCI and that Rac1 in
astrocytes is a potential target for developing new therapeutic
modalities for CNS injury. Moreover, we identified GSPT1 as a
novel downstream target of Rac1 that promotes cell prolifera-
tion through the progression of the G1 to S phase transition.
GSPT1 may be a more powerful target for cancer therapy in
addition to therapy against CNS injury. Further study will be
required to define the precise mechanisms by which Rac1 reg-
ulates GSPT1.
Experimental Procedures
Animals—All animal experiments were conducted in ac-
cordance with Kobe University and University of Toyama
guidelines. GFAP-Cre mice (23) and Rac1flox mice (24) have
been described previously. GFAP-Cre;Rac1flox/ progeny of
Rac1flox/flox and GFAP-Cre mice were back-crossed with
Rac1flox/flox to obtainGFAP-Cre;Rac1flox/flox (hereafter referred
to as Rac1 KO) mice, which were backcrossed to Rac1flox/flox to
generate the GFAP-Cre;Rac1flox/flox and Rac1flox/flox experi-
mental mice. CAG-STOPflox–tdTomato (Ai9) mice, in which
the ROSA26 region was used for transgene insertion, were pur-
chased fromThe Jackson Laboratory (Bar Harbor, ME).GFAP-
Cre;Rac1flox/;tdTomato progeny ofGFAP-Cre;Rac1flox/flox and
CAG-STOPflox-tdTomato mice were used to examine the effi-
cacy of theGFAP promoter in astrocytes of the spinal cord. The
GFAP-Cre;Rac1flox/;tdTomato mice were back-crossed with
Rac1flox/flox to obtain GFAP-Cre;Rac1flox/flox;tdTomato mice,
which were then backcrossed to Rac1flox/flox to generate the
GFAP-Cre;Rac1flox/flox;tdTomato and Rac1flox/flox;tdTomato
experimental mice. Astrocytes obtained from GFAP-Cre;
Rac1flox/flox;tdTomatomice are labeled with tdTomato fluores-
cence, which is a marker of Rac1-KO. Control astrocytes
obtained from Rac1flox/flox;tdTomato mice are negative for
tdTomato fluorescence and are thus not Rac1-KO cells. Off-
spring were genotyped by PCR using the following primers:
5-ACTCCTTCATAAAGCCCTCG-3 and 5-ATCACTCG-
TTGCATCGACCG-3 for GFAP-Cre; 5-ATTTTCTAGAT-
TCCACTTGTGAAC-3 and 5-ATCCCTACTTCCTTC-
CAACTC-3 for Rac1flox; 5-GGCATTAAAGCAGCG-
TATCC-3 and 5-CTGTTCCTGTACGGCATGG-3 for
tdTomato. WT C57BL/6 mice were purchased from Clea
Japan.
SCI Model Experiments—14–20-week-old Rac1 KO mice
and controlmicewere used. Themicewere anesthetized via the
administration of trichloroacetaldehyde monohydrate (500
mg/kg, i.p.). After the mice had completely lost their righting
reflex, surgical procedures to produce SCI were performed, as
described previously (26) with slight modifications. Contusion
FIGURE5.ReducedexpressionofGSPT1 inRac1-KDand -KOastrocytes.A,
primary astrocytes obtained from control and Rac1-KO mice were treated
with or without LPS (0.5g/ml) for 24 h. Expression levels of IL-1were eval-
uated by immunoblotting using an IL-1 antibody. Rac1-KO and comparable
loadingof proteinswere confirmedusing a Rac1 antibody and tubulin- anti-
body, respectively. The arrow indicates the IL-1 bands. B, LN229 astrocytic
cells transfected with pSUPER (sh-cont) or shRac1(618) were treated with LPS
(0.5g/ml) for 24 h. Reduced expression levels of Rac1 and IL-1 and compa-
rable loading of proteins were confirmed using a Rac1 antibody, IL-1 anti-
body, and tubulin- antibody, respectively. The arrow indicates the IL-1
bands.C, Rac1was knockeddownvia transfection of 2.5 nMof siRNAs (si-cont,
siRac1(618), or siRac1(1977)) in LN229 cells. Primary astrocyteswereprepared
from control and Rac1-KO mice. Reduced expression levels of GSPT1 were
evaluated using a GSPT1 antibody. Rac1-KD/KO and comparable loading of
proteinswere confirmedusingaRac1 antibodyandGAPDHantibody, respec-
tively. D, 2.5 nM of siRNAs (si-cont or siRac1(618)) were transfected in LN229
cells 24 h prior to LPS treatment. After LPS treatment (0.5 g/ml) for 24 h,
GSPT1 levels were evaluated using a GSPT1 antibody. Rac1-KD and compara-
ble loading of proteins were confirmed using a Rac1 antibody and GAPDH
antibody, respectively. E, LN229 cells were simultaneously treated with LPS
(1.0 g/ml) and one of four inhibitors at the indicated concentrations (M;
JNK-IN-8, SB203580, U0126, or BAY 11-7085) for 16 h. After the treatment,
GSPT1 levels were evaluated using a GSPT1 antibody. Comparable loading of
proteins was confirmed using a GAPDH antibody.
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injuries were produced by dropping a 6.5-g weight from a
height of 7mmonce onto the exposed duramater of the lumbar
L1 level of the spinal cord using a stereotaxic instrument
(Narishige, Tokyo, Japan). Themicewere allowed to recover for
35 days. For behavioral scoring, the mice were placed individ-
ually in an open field (23.5 cm  16.5 cm  12.5 cm) and
observed for 5 min. Open field locomotion focused on each
hind limb was evaluated using the 0–8-point BMS locomotion
scale (25) and the 0–4-point BSS locomotion scale (26).
Microplanar Microbeam Irradiation at SPring-8—8–12-
week-old Rac1-KO mice and control mice were used. The
SPring-8 synchrotron facility (Japan Synchrotron Radiation
Research Institute, RIKEN, Sayo, Japan) was used to supply
microplanar beam irradiation. The radiation beam traveled in a
vacuum transport tube with minimized air scattering of the
primary beam. X-rays were emitted from the vacuum tube into
the atmosphere after first passing through a beryllium vacuum
window and then into a 2.0-m helium beam path consisting of
an aluminum tube and a thin aluminumheliumwindow located
42 m from the synchrotron radiation output. The sample posi-
tioning system was placed 2.5 m from the thin aluminum win-
dow. This beamline produces nearly parallel X-rays, and the
mice were irradiated at a position 2.5 m from the thin alumi-
numwindow.White beamX-rays with an energy level of100
FIGURE6.Cell cycledelaybyGSPT1-KDand rescueof cell cycledelay inducedbyRac1-KDviaoverexpressionofGSPT1.A, 5 and10nMof control (si-cont)
or two GSPT1 siRNAs (si620 or si1374) were co-transfectedwith Venus-hGeminin plasmid into HeLa cells. At 48 h after transfection, expression levels of GSPT1
were evaluated using aGSPT1 antibody. Comparable loadingof proteinswas confirmedusing aGAPDHantibody.B, 14–96 h after transfection (10 nM of siRNA
Venus-hGeminin plasmid) into HeLa cells, the cell cycle time of Venus-hGeminin transfected cells was observed under an LCV110microscope (si-cont: n 68,
si620: n 85, si1374: n 56; **, p 0.0001). C, 2.5 and 5 nM of si-cont or siRac1(618) was co-transfected with the GFP plasmid into HeLa cells. For the rescue
experiment, Rac1 siRNA GFP-GSPT1 plasmid was co-transfected into HeLa cells. At 48 h after transfection, expression levels of Rac1, GSPT1, overexpressed
GFP-GSPT1, and GFP were examined by immunoblotting using a Rac1, GSPT, and GFP antibody, respectively. Comparable loading of proteins was confirmed
using aGAPDHantibody.D, from24 to96hafter transfection (siRac1(618)GFPorGFP-GSPT1plasmid) intoHeLa cells, the cell cycle timeofGFPorGFP-GSPT1
transfected cells was observed under an LCV110 microscope (2.5 nM siRac1, GFP: n 171, GFP-GSPT1: n 171; **, p 0.0003; and 5 nM siRac1, GFP: n 148,
GFP-GSPT1: n 77; **, p 0.0001). E, 10 and 20 nM of si-cont or siGSPT1(620m)were co-electroporatedwith the GFP plasmid into the primary astrocytes. 60 h
after electroporation, the expression levels of GSPT1 were evaluated using a GSPT1 antibody. Comparable loading of proteins was confirmed using a GAPDH
antibody. F, from48 to 120 h after electroporation (20 nMof siRNAGFPplasmid) ofWTprimary astrocytes, the cell cycle time of theGFP-transfected cells was
assessed using an LCV110 microscope (si-cont: n 107, si620m: n 90; **, p 0.0001).
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keV were derived through 3-mm Cu absorbance. The mice
were irradiated with a single slit collimator at the same beam-
line, withmultiple horizontalmicroplanar beams 100-mthick
at an extremely high dose of 550 Gy with 400-mgaps between
beams on the brain. Anesthetized mice were positioned hori-
zontally in front of the horizontally propagating beams, with
the right brain aligned perpendicular to the direction of the
beam. The multislit collimator, which produces 10 peak dose
areas composed of 100-m width with 400-m gaps between
them to process the microplanar beam, was set downstream of
the output of the beamline hatch. The details of this multislit
irradiation system have been described previously (28).
Chemicals and Antibodies—LPS was obtained from Invivo-
Gen (San Diego, CA). JNK-IN-8 (Millipore, Billerica, MA), a
JNK inhibitor; SB203580 (Cell Signaling Technology, Danvers,
MA), a p38MAP kinase inhibitor; U0126 (Cell Signaling Tech-
nology), an ERK inhibitor; and BAY 11-7085 (Wako Pure
Chemical Industries, Japan), an NF-B inhibitor were pur-
chased from the respective vendors. The following specific anti-
bodies were used (polyclonal unless indicated): Rac1 monoclo-
nal (23A8, Millipore); GFAP (DAKO, Carpinteria, CA); IL-1
(H-153, Santa Cruz Biosciences, Santa Cruz, CA), and GSPT1
(10763-1-AP; Proteintech, Rosemont, IL) and eRF3 (antibody
against GSPT, 14980; Cell Signaling Technology). Alexa 488-
conjugated secondary antibodies were obtained from Invitro-
gen. HRP-conjugated GAPDH or tubulin- antibodies were
obtained fromMBL International.
Plasmids and siRNA—Venus-tagged hGeminin plasmid,
which is an indicator of the S-M phase and one of two compo-
nents of the Fucci system (29), was provided as a kind gift from
Dr. Miyawaki (RIKEN, Wako, Japan). Human GSPT1 cDNAs
were obtained from RIKEN (Tsukuba, Japan) and cloned into
pEGFP-C3 (Clontech, Mountain View, CA) and p3FLAG-
CMV-10 (Sigma-Aldrich). Myc-tagged human Rac1 plasmid
and a validated target sequence of human/mouse Rac1 for
RNAi (human nucleotides 618–636 from ATG: CCTTTG-
TACGCTTTGCTCA) were developed as previously described
(6). shRNA expression plasmids for Rac1 containing the vali-
dated sequence were prepared using pSUPER, pSUPER(gfp)
(OrigoEngine, Seattle, WA), and pSUPER(rfp), in which gfp of
pSUPER(gfp) was replaced by mCherry. The plasmids were
named pSUPER(618) (55), shRac1(618gfp), and shRac1(618rfp),
respectively.
The target sequences for RNAiwereCCTTTGTACGCTTT-
GCTCA andGCCACTACAACAGAATTTT for human RAC1
(618–636 and 1977–1995 from ATG, named siRac1(618)
(100% conserved in mouse) and siRac1–1977, respectively),
CTAAGAAAGAGCATGTAAA and GGAATCAGGATCTA-
TTTGT for human GSPT1 (620–638 and 1374–1392 from
ATG, named siGSPT1–620 and siGSPT1–1374, respectively),
and CCAAGAAGGAACATGTAAA for mouse GSPT1 (620–
638 from ATG, named siGSPT1(620m)). siRNAs and control
siRNA (MISSIONUniversal Negative Control) were purchased
from Sigma-Aldrich.
siRNA and shRNA plasmids were transfected into LN229
and HeLa cells using Lipofectamine 3000 (Invitrogen) or
RNAiMAX (Invitrogen). siRNAs were transfected into primary
astrocytes using a NEPA21 electroporator (Nepa Gene Co.,
Ltd., Japan). Compared with lipofection, electroporation has
been reported to require a higher concentration of siRNAs (56).
Thus, 20 nM siRNA was used for electroporation.
Cells—LN229 astrocytic cells and HeLa cells were main-
tained in DMEM (Wako) containing 10% FBS (Nichirei Biosci-
ences, Japan). Primary astrocyte cultures were prepared from
mouse cerebral cortex at postnatal day 1 or 2. Dissected cere-
bral cortexes were dissociated in Eagle’s minimal essential
medium (Wako) supplemented with 10% FBS, 100 units/ml
penicillin, and 100 g/ml streptomycin and were cultured in
25-cm2 flasks (2 brains/flask) (Corning Inc., Corning, NY).
After 5–7 days, the flasks were subjected to 2 h of continuous
shaking to obtain purified astrocytes. Trypsinized cells and
cell lysates were used for the experiments, as indicated (only
one trypsinization step was used for the primary astrocytes).
The percentage of primary astrocytes obtained from GFAP-
Cre;Rac1flox/flox;tdTomato mice with tdTomato fluorescence
was 80–90%. All cells were maintained in a 5% CO2 humidified
incubator at 37 °C.
RT-PCR—RT-PCR was performed with 1 g of total RNA
obtained from the primary astrocytes ofWTmice using Super-
Script III reverse transcriptase (Invitrogen) and random prim-




CTATGAACATCC-3 for Rac2, and 5-CCCACACACAC-
CCATCCTTC-3 and 5-TGGAGCTATATCCCAGAAAA-
AGGAG-3 for Rac3.
FIGURE 7.No effect of GSPT1-KD on astrocytemigration. A, 5 and 10 nM of
control (si-cont) or two GSPT1 siRNAs (si620 or si1374) were co-transfected
with GFP plasmid into LN229 astrocytic cells. At 48 h after transfection,
expression levels of GSPT1 were evaluated using a GSPT1 antibody. Compa-
rable loading of proteins was confirmed using a GAPDH antibody. B, from 48
to 96 h after transfection (10 nM of siRNA GFP), the cell migration capabili-
ties of the LN229 cells were monitored using an LCV110microscope (si-cont:
n 51, si620:n 50, si1374:n 50).C, 20 nMof si-cont or siGSPT1(620m)was
co-electroporatedwith theGFPplasmid intoWTprimary astrocytes. 32hafter
electroporation, theexpression levels ofGSPT1wereevaluatedusingaGSPT1
antibody. Comparable loading of proteins was confirmed using a GAPDH
antibody. D, 32 h after electroporation (20 nM of siRNA GFP plasmid) into
WT primary astrocytes, cell migration capabilities were assayed using a Cyto-
Select migration assay kit (si-cont: n 8, si620m: n 4).
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Cell Cycle Analysis—LN229 and HeLa cells were cultured on
35-mm glass-bottomed dishes (gbd; MatTek, Ashland, MA).
LN229 cells were transfected with Venus-tagged hGeminin 
shRNA expression plasmid (pSUPER(rfp) or shRac1(618rfp))
using Lipofectamine 3000. HeLa cells were transfected with
Venus-tagged hGeminin  siRNA (control or siGSPT1). For
rescue experiments, HeLa cells with transfection of siRac1(618)
were simultaneously transfected with pEGFP-C1 or GFP-
GSPT1 using Lipofectamine 3000. Starting at 24 h after trans-
fection, the cells were imaged every 20 min for 72 h at 37 °C in
5% CO2 using a computer-assisted incubator fluorescence
microscope system (LCV110; Olympus). This system enabled
ultra long term imaging of living cells without removal of the
cells from the culture conditions. LN229 cells with RFP fluores-
cence and HeLa cells with Venus or GFP fluorescence were
analyzed as cells with shRNA or siRNA. Cell cycle (doubling
time) was defined as the time from one cytokinesis to the next
cytokinesis. The experiments were performed in duplicate, and
at least three independent transfection experiments were
conducted.
siRNA (control, siRac1(618) or siGSPT1(620m))was electro-
porated into WT primary astrocytes in combination with
the pEGFP-C1 plasmid. Primary astrocytes obtained from
GFAP-Cre;Rac1flox/flox;tdTomato (Rac1-KO) mice and control
(Rac1flox/flox;tdTomato)mice or primary astrocytes subjected to
electroporation were cultured on 35-mm gbd. Starting at 48 h
after plating on gbd, the cells were imaged every 20min for 72 h
using a live imaging LCV110 system, as described above. Astro-
cytes with tdTomato fluorescence and GFP fluorescence were
considered to be Rac1-KO cells and cells containing siRNA,
respectively.
Scratch Wound (Wound Healing) Assay—LN229 cells were
transfected with shRNA expression plasmid (pSUPER(gfp) or
shRac1(618gfp)), or pEGFP(C1) siRNA (control or siGSPT1)
using Lipofectamine 3000. At 24 h after transfection, culture
media were changed to serum-freemedia, and cells were grown
for an additional 24 h. Forty-eight hours after transfection,
an approximately 1,000-m-wide section of the cells was
scratched using a sterilized 1,000-l filter tip, and imaged every
20 min for 48 h using a live imaging LCV110 system (see the
“cell cycle analysis” section for details). Cells with GFP fluores-
cencewere analyzed as cells with shRNAor siRNA. Cells whose
cell bodies has translocated were considered to be migrated
cells. Cell migration was defined as the distance from the lead-
ing edge of the cell at the starting time point to the same point
on the cell at the ending time point. Experiments were per-
formed in duplicate, and at least three independent transfec-
tions were conducted.
siRNA (control, siRac1(618), or siGSPT1(620m)) was elec-
troporated into WT primary astrocytes in combination with
the pEGFP(C1) plasmid. Primary astrocytes obtained from
GFAP-Cre;Rac1flox/flox;tdTomato (Rac1-KO) mice and control
mice or primary astrocytes treated with electroporation were
cultured on 35-mm gbd. Forty-eight hours after plating on gbd,
the cells were imaged every 20min for 72 h using a live imaging
LCV110 system. Astrocytes with tdTomato fluorescence and
GFP fluorescence were considered to be Rac1-KO cells and
cells containing siRNA, respectively.
Cell Migration Assay—Migration of primary astrocytes was
evaluated using the CytoSelect cell migration assay kit (12 m
pore size, colorimetric format; Cell Biolabs, Inc., San Diego,
CA) according to the manufacturer’s protocol. Briefly, 2.0 
105 primary astrocytes obtained from GFAP-Cre;Rac1flox/flox;
tdTomato (Rac1-KO) mice and control (Rac1flox/flox;
tdTomato) mice or 5.0  105 WT primary astrocytes treated
with electroporation (pEGFP-C3 20 nM of siRNA (control or
siGSPT1(620m)) suspended in serum-free DMEMwere placed
in 24-well insets, and 500l of DMEMcontaining 10% FBSwas
added to the lower wells of the 24-well plate. After 24 h (Rac1-
KO) or 32 h (GSPT1-KD), non-migrating cells on the interior
surface of the inset were removed, and migrated cells on the
exterior surface of the inset were stained using stain solution.
After extraction of themigrated cells in extraction solution, the
A value at 560 nmwas obtained using a plate reader (Multiskan
GO; Thermo Fisher Scientific). The data are shown as percent-
ages of control.
Section Preparation and Immunohistochemistry—At 35 days
after SCI and 21 days after microbeam irradiation injury, the
animals were deeply anesthetized using pentobarbital and tran-
scardially perfused with ice-cold 0.9% saline solution and then
with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4)
(57). Spinal cords and brains were dissected, post-fixed over-
night in the same fresh fixative, and then embedded in paraffin.
Three-m sagittal sections of the spinal cord and cerebellum
with brainstem were obtained (from 5-mm rostral and caudal
to the injury site in the case of SCI). After deparaffinization and
permeabilizationwith PBS containing 0.3%TritonX-100 (PBS-
0.3T), spinal cord sections were incubated overnight with a
GFAP antibody in PBS containing 0.03% Triton X-100 (PBS-
0.03T) at 4 °C, followed by incubation with Alexa 488-conju-
gated secondary antibodies for 1 h at 24 °C. The cerebellum
with brainstem sections were incubated overnight with aGFAP
antibody in PBS containing 0.03% Triton X-100 (PBS-0.03T) at
4 °C, followed by diaminobenzidine staining using a Vectastain
ABC kit (Vector Laboratories, Burlingame, CA) and counter-
staining using Cresyl violet solution (Muto Pure Chemicals,
Tokyo, Japan). Quantification of GFAP immunoreactivity was
performed as follows. For SCI cases, fluorescent images were
captured using a fluorescence microscopy system (Biozero,
Keyence, Japan). Immunoreactivity in a 100-m area from the
lesion edge was measured using ImageJ software (National
Institutes of Health, Bethesda, MD). Areas that appeared
brighter than the background were defined as GFAP-positive
areas. The number of pixels were calculated, and the GFAP-
positive area was defined as a percentage of the number of pix-
els for the entire area. For microbeam irradiation injury cases,
diaminobenzidine stainings were photographed using a light
microscope (Axioplan II; Carl Zeiss) with a DP26 camera
(Olympus). Immunoreactivity areas that appeared brighter
than the background (as analyzed by ImageJ software) were
defined as GFAP-positive areas, which were defined in a linear
band. The region of interest (ROI) was defined as a 400-m
square with its center in the linear immunoreactivity band of
the GFAP-positive area, and the GFAP-positive immunoreac-
tivity area was calculated as a percentage of the total area.
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Immunoblotting—The cells were lysed in homogenizing
buffer (58) by sonication in the presence of protease inhibitor
mixture, protein phosphatase inhibitor mixture (Nacalai
Tesque, Tokyo, Japan), and 1%TritonX-100. Total lysates were
centrifuged at 800  g for 5 min at 4 °C, and the supernatants
were subjected to SDS-PAGE, followed by immunoblotting for
2 h at 24 °C using primary antibodies diluted in PBS-0.03T. The
bound primary antibodies were detected with secondary
Ab-HRP conjugates using the ECL detection system (GE
Healthcare).
DNA Microarray—LN229 cells were transfected with
pSUPER or shRac(618). At 24 h after transfection, LN229 cells
were treatedwith LPS (0.5g/ml) for 24 h, and then total RNAs
were extracted using TRIzol (Invitrogen). The quality and
quantity of RNA were determined using the Agilent 2100 Bio-
Analyzer. Gene expression profiles were examined using the
SurePrint G3 Mouse Gene Expression 8  60K microarray kit
(Agilent Technologies, Lexington, MA).
Statistical Analysis—All data are presented as the means 
S.E. For comparisons of two groups, unpaired Student’s t tests
were used. For comparisons of more than two groups, one-way
analysis of variance (ANOVA) or repeated measures two-way
ANOVA was performed and followed by Bonferroni post hoc
test of pairwise group differences. Statistical analyses were per-
formed using Prism 6.0 software (GraphPad, La Jolla, CA); p
0.05 was considered statistically significant.
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